An orally active tubulin polymerization inhibitor with potent cytotoxic and vascular disrupting activity in vitro and in vivo; inhibits a broad selection of cancer cell lines with IC50 of <100 nM; blocks the cell cycle at the G2-M boundary and increases phosphorylated Bcl-2, expression of cyclin B1; orally bioavailable, and efficacious in a range of in vivo cancer models.
Phase 2 Discontinued
A taxol derivative with antitumor, antiproliferative properties.
A semisynthetic Epothilone B analogue and potent, orally active microtubule stabilizer; shows a broad spectrum of activity against a panel of tumor cell lines in vitro (IC50=1.4-34.5 nM), retains the antineoplastic activity against human cancers that are resistance to paclitaxel both in vitro and in vivo.
A potent inhibitor of microtubule assembly, and a key intermediate compound for the preparation of podophyllotoxin-type anti-cancer compounds.
A derivative of combretastatin that acts as a microtubule destabilising agent; damage the vasculature (blood vessels) of cancer tumours causing central necrosis.
Phase 3 Clinical
A cytotoxic alkaloid that binds tubulin and inhibits the assembly of microtubules; a chemotherapy agent for treatment of a number of types of cancer.
Join with Us
Product Use Citations
Pharmacological Glossary Abbreviations
How to Order
Terms & Conditions
Credit Card Payment
Shipping Rates & Policies